Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A randomised, controlled, double-blind, parallel group, multi-country study to investigate the safety and tolerance of a partly fermented infant formula containing prebiotic oligosaccharides in healthy term infants.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention | Experimental | Cows milk based infant formula containing fermented infant formula and prebiotic oligosaccharides |
|
| Control | Active Comparator | Cows milk based infant formula containing prebiotic oligosaccharides (commercially available Aptamil ProNutra) |
|
| Breastfed reference | No Intervention | Exclusively breastfed from birth to study completion |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Infant formula | Other | Infants are randomized to one of two infant formulas from <14 days of age to 17 weeks of age. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Weight gain (infant formula comparison) | Equivalence of weight gain per day (g/d) from baseline until 17 weeks of age in subjects receiving the test product compared to infants receiving the control product | 17 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Weight gain (human milk comparison) | Equivalence of weight gain per day (g/d) from baseline until 17 weeks of age in subjects receiving the test product compared to infants receiving human milk | 17 weeks |
| Recumbent Length gain |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Infants who require to be fed a special diet other than standard cow's milk based infant formula;
Infants known or suspected to have cow's milk allergy, soy allergy and/or lactose intolerance;
Infants known or suspected to have current or previous illnesses/conditions or interventions which could interfere with the study or its outcome parameters, as per the clinical judgement of the Investigator;
Infants with known or suspected congenital diseases or malformations which could interfere with the study or its outcome parameters (including, but not limited to: GI malformations, congenital immunodeficiency), as per the clinical judgement of the Investigator;
Infants with previous, current or intended participation in any other clinical study involving investigational or marketed products;
Incapability of infants' parents/legally acceptable representatives to comply with study protocol or Investigator's uncertainty about the willingness or ability of the parent(s)/legally acceptable representative(s) to comply with the protocol requirements;
Infants born from mothers with significant medical conditions during pregnancy that might interfere with the study or known to affect intra-uterine growth (e.g. placenta previa, pre-eclampsia, eclampsia, gestational diabetes requiring insulin or oral medication) as per Investigator's judgement.
Criteria for lactating mothers of subjects in the breastfed reference arm:
Lactating women who are currently participating or intend to participate in any other clinical study involving investigational products. Participation in purely observational studies is permitted;
Lactating women known to suffer from hepatitis B or human immunodeficiency virus;
Lactating women known to have any other significant medical condition(s) which might interfere with the study or its outcome parameters (breast abscess or mastitis which could interfere with lactation, or other clinically relevant infections, or consumption of medication/substances which could impact the infants' growth), as per the clinical judgement of the Investigator;
Lactating women who intend to feed their infants with a combination of human milk and infant formula.
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jan van der Mooren, MD, PhD | Contact | +31 30 295000 | jan.vandermooren@danone.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Poliklinika Ginekologiczno-Położnicza Sp. z o.o. Sp. k. | Recruiting | Bialystok | 15-435 | Poland |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D041943 | Infant Formula |
| ID | Term |
|---|---|
| D041941 | Milk Substitutes |
| D001628 | Beverages |
| D000066888 | Diet, Food, and Nutrition |
| D010829 | Physiological Phenomena |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Equivalence of length gain per day (mm/d) from baseline until 17 weeks of age in subjects receiving the test product compared to infants receiving the control product or human milk
| 17 weeks |
| Head circumference gain | Equivalence of head circumference gain per day (mm/d) from baseline until 17 weeks of age in subjects receiving the test product compared to infants receiving the control product or human milk | 17 weeks |
| Parent-reported GI Tolerance Parameters (daily diary) | Information on regurgitation and vomiting will be collected by a daily diary that is completed by the parents. | 17 weeks |
| Parent-Reported Stool Characteristics (adapted Amsterdam Stool Scale) | Information on stool consistency (4-point scale) and stool frequency (number of stools per day) will be collected by a daily diary that is completed by the parents. Occurrence of diarrhea like-symptoms and constipation-like symptoms will be derived from the stool frequency and consistency data. | 17 weeks |
| Incidence of treatment-related adverse events | Number of adverse events (by "System/Organ Class" and "Preferred term" according the MedDRA) as assessed and reported by the investigator. | 17 weeks |
| Severity of treatment-related adverse events | Severity of adverse events (by "System/Organ Class" and "Preferred term" according the MedDRA) as assessed and reported by the investigator. | 17 weeks |
| D005526 |
| Food, Formulated |
| D019648 | Foods, Specialized |
| D005502 | Food |
| D007225 | Infant Food |
| D019602 | Food and Beverages |